Premium
Topotecan (Hycamptin) and Topotecan‐Containing Regimens in the Treatment of Hematologic Malignancies
Author(s) -
BERAN MILOSLAV,
KANTARJIAN HAGOP M.
Publication year - 2000
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2000.tb07043.x
Subject(s) - topotecan , medicine , cytarabine , anthracycline , chemotherapy , oncology , multiple myeloma , regimen , refractory (planetary science) , pharmacology , cancer , biology , astrobiology , breast cancer
A bstract : Single‐agent topotecan is an active drug in chemotherapy‐naive MDS and CMML and, to a lesser degree, in refractory/relapsed acute leukemias, low‐/intermediate‐grade lymphoma, and myeloma. Its combination with cytosine arabinoside induces complete remissions in high‐risk MDS/CMML. A triple‐combination regimen of cyclophosphamide, cytosine arabinoside, and topotecan (CAT) was extensively tested in refractory/relapsed as well as in untreated AML. By proving effective in inducing complete remission in newly diagnosed AML at rates comparable to those achieved by anthracycline‐cytosine arabinoside regimens, for example, CAT offers a useful treatment alternative. Topotecan combined with paclitaxel is promising in low‐/intermediate‐grade lymphomas. The activity of topotecan justifies further evaluation of topotecan‐containing combination regimens, particularly in MDS/CMML and acute leukemias.